Nguyen Mike M, Gill Inderbir S, Ellison Lars M
Department of Urology, University of California at Davis, 4860 Y Street, Sacramento, CA 95817, USA.
J Urol. 2006 Dec;176(6 Pt 1):2397-400; discussion 2400. doi: 10.1016/j.juro.2006.07.144.
The incidence of renal cancer is increasing, while cases series suggest that tumor size is decreasing. This has important implications for treatment planning. We evaluated national trends in renal cancer size and observed survival in patients diagnosed in the 3 periods 1988 to 1992, 1993 to 1997 and 1998 to 2002.
From the Surveillance, Epidemiology, and End Results database we identified 29,053 patients diagnosed with primary renal cancer. Patients were stratified into size categories and 5-year time cohorts. Size distribution was compared across cohorts. Kaplan-Meier survival curves and Cox proportional hazards modeling were used to examine trends in overall and stage specific survival.
From 1988 through 2002 renal tumor size decreased from 66.8 to 58.6 mm, while the age adjusted incidence of renal cancer increased from 8.6 to 11.2 cases per 100,000 individuals. Kaplan-Meier analysis showed steadily deteriorating survival with increased cancer size above 4 cm with a median survival of 105 months for 4 to 7 cm vs 46 months for more than 7 cm. Cox modeling demonstrated significantly improved survival in patients diagnosed in the latter cohorts. With adjustment for size the latter cohorts remained significantly improved compared to the earliest cohort, although the 1998 to 2002 cohort was no longer significantly different than the 1993 to 1997 cohort.
Nationally renal tumor size at presentation has steadily and consistently decreased. Patients more recently diagnosed had improved survival, which could be attributable to decreased tumor size in the latter cohorts. Patients more recently diagnosed also demonstrated a relative survival advantage independent of size compared to the earliest patients studied.
肾癌的发病率正在上升,而病例系列研究表明肿瘤大小却在减小。这对治疗规划具有重要意义。我们评估了1988年至1992年、1993年至1997年以及1998年至2002年这三个时期诊断出的肾癌患者的肿瘤大小全国趋势及观察到的生存率。
从监测、流行病学和最终结果数据库中,我们确定了29053例诊断为原发性肾癌的患者。将患者按肿瘤大小类别和5年时间队列进行分层。比较各队列的大小分布。采用Kaplan-Meier生存曲线和Cox比例风险模型来研究总体生存率和特定分期生存率的趋势。
从1988年到2002年,肾肿瘤大小从66.8毫米降至58.6毫米,而年龄调整后的肾癌发病率从每10万人8.6例增至11.2例。Kaplan-Meier分析显示,肿瘤大小超过4厘米时,生存率稳步下降,4至7厘米的患者中位生存期为105个月,而超过7厘米的患者为46个月。Cox模型表明,后几个队列中诊断出的患者生存率显著提高。在对肿瘤大小进行调整后,后几个队列与最早的队列相比仍有显著改善,尽管1998年至2002年队列与1993年至1997年队列不再有显著差异。
在全国范围内,就诊时的肾肿瘤大小一直在稳步且持续地减小。最近诊断出的患者生存率有所提高,这可能归因于后几个队列中肿瘤大小的减小。与最早研究的患者相比,最近诊断出的患者在不考虑肿瘤大小的情况下也表现出相对生存优势。